NasoShield Study of Safety and Immunogenicity

Inclusion criteria

• . Men and women 18 to 49 years of age, inclusive
• . Good general health status as determined by the Investigator
• . Adequate venous access for repeated phlebotomies
• . Screening laboratory results within institutional normal range or Grade 1 abnormality if the Investigator documents clinical insignificance. Creatine kinase or bilirubin may be Grade 2 if associated with normal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and the Investigator considers the result not to be clinically significant due to vigorous exercise or Gilbert's syndrome
• . Negative drug and alcohol screen at Screening and predose on Day 1
• . For women who have not been surgically sterilized and do not have laboratory confirmation of postmenopausal status, negative pregnancy test
• . Willingness to practice a highly effective method of contraception: abstinence, sex only with persons of the same sex, monogamous relationship with a postmenopausal partner, monogamous relationship with vasectomized partner, vasectomy, surgical sterilization (hysterectomy, bilateral tubal ligation, salpingectomy, or oophorectomy), licensed hormonal methods, intrauterine device (IUD), or consistent use of a barrier method (eg, condom, diaphragm) with spermicide for 28 days after the last IP dose
• . Willingness to participate and comply with all aspects of the study through the entire study period, including nasopharyngeal swabs and blood and urine samples

Exclusion criteria